INT12474

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 1991
Last Reported 2010
Negated 0
Speculated 3
Reported most in Abstract
Documents 18
Total Number 21
Disease Relevance 6.29
Pain Relevance 4.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 1
SH-SY5Y 1
platelet 1
bowel 1
terminal portion 1
INSRR (Homo sapiens)
Pain Link Frequency Relevance Heat
halothane 6 100.00 Very High Very High Very High
opiate 4 100.00 Very High Very High Very High
Glutamate receptor 1 100.00 Very High Very High Very High
agonist 57 99.96 Very High Very High Very High
antagonist 22 99.96 Very High Very High Very High
gABA 13 99.96 Very High Very High Very High
adenocard 4 99.66 Very High Very High Very High
Migraine 9 99.64 Very High Very High Very High
Sumatriptan 6 99.64 Very High Very High Very High
opioid receptor 28 99.48 Very High Very High Very High
Disease Link Frequency Relevance Heat
Headache 7 99.64 Very High Very High Very High
Pain 16 99.28 Very High Very High Very High
Vomiting 16 98.92 Very High Very High Very High
Neuroblastoma 3 98.68 Very High Very High Very High
Repression 4 98.32 Very High Very High Very High
Disease 41 98.16 Very High Very High Very High
Functional Bowel Disorder 6 97.92 Very High Very High Very High
Cleidocranial Dysplasia 1 97.04 Very High Very High Very High
Frailty 1 96.52 Very High Very High Very High
Renal Cancer 3 95.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In order to investigate the sequence and pattern of neurodegeneration in Huntington's disease, the distribution and density of cannabinoid CB(1), dopamine D(1) and D(2), adenosine A(2a) and GABA(A) receptor changes were studied in the basal ganglia in early (grade 0), intermediate (grades 1, 2) and advanced (grade 3) neuropathological grades of Huntington's disease.
Regulation (changes) of ) receptor in basal ganglia associated with gaba, adenocard, dopamine, cannabinoid and disease
1) Confidence 0.29 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.49 Pain Relevance 0.48
The 5-HT1D receptor is a potential target of anti-migraine drugs, and here its genes were cloned from chimpanzee, gorilla and rhesus monkey, via polymerase chain reactions with their genomic DNAs and the primers designed from the 5' and 3' untranslated regions of the human receptor.
Regulation (target) of receptor associated with migraine
2) Confidence 0.16 Published 1997 Journal Neurosci. Lett. Section Abstract Doc Link 9406883 Disease Relevance 0.10 Pain Relevance 0.10
The inhibitory GABA(A) receptor, alpha1 glycine receptor, beta(2)-adrenergic receptor and arrestin, opiate receptors and the excitatory metabotropic glutamate receptor (mGluR1alpha) are regulated by the UPP.
Regulation (regulated) of ) receptor associated with gaba, glutamate receptor and opiate
3) Confidence 0.11 Published 2003 Journal Drug News Perspect. Section Abstract Doc Link 12792671 Disease Relevance 0.77 Pain Relevance 0.25
The receptor is targeted by drugs administered for nausea and/or emesis and irritable bowel syndrome and has been proposed as a potential drug target in various psychiatric disorders.
Regulation (targeted) of receptor in bowel associated with spastic colon and vomiting
4) Confidence 0.09 Published 2008 Journal Trends Pharmacol. Sci. Section Abstract Doc Link 18597859 Disease Relevance 0.30 Pain Relevance 0.10
The method described can be used to investigate alterations in receptor distribution which occur in neuropsychiatric diseases involving neuronal dysplasia or atrophy.
Spec (investigate) Regulation (alterations) of receptor in neuronal associated with frailty, cleidocranial dysplasia and disease
5) Confidence 0.08 Published 1991 Journal J. Neurosci. Methods Section Abstract Doc Link 1648154 Disease Relevance 0.55 Pain Relevance 0.14
The aim of this study was to examine the acute effects of ET(A) receptor antagonism on coronary artery compliance in humans.
Spec (examine) Regulation (effects) of ) receptor in coronary artery
6) Confidence 0.06 Published 2002 Journal Clin. Sci. Section Abstract Doc Link 12193081 Disease Relevance 0.17 Pain Relevance 0.14
Thus, these findings outline diverse potential molecular targets to modulate P2X(3) receptor function in relation to its functional state.
Regulation (modulate) of receptor
7) Confidence 0.04 Published 2004 Journal J. Biol. Chem. Section Abstract Doc Link 15475563 Disease Relevance 0 Pain Relevance 0.03
We studied the effect of the 5-HT1B/ID receptor agonist sumatriptan (6 mg s.c.) on plasma growth hormone and prolactin and food intake in 15 healthy female subjects using a double-blind, placebo-controlled, cross-over design.
Regulation (effect) of receptor in plasma associated with sumatriptan and agonist
8) Confidence 0.02 Published 1997 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 9040124 Disease Relevance 0 Pain Relevance 0.44
OBJECTIVES: To determine if morphine is capable of down regulating the ER-beta receptor in a similar fashion as the mu opiate receptor since they are both coupled to constitutive nitric oxide synthase derived nitric oxide release.
Regulation (regulating) of receptor
9) Confidence 0.01 Published 2002 Journal Neuro Endocrinol. Lett. Section Body Doc Link 12011792 Disease Relevance 0 Pain Relevance 0
In this study we have used SH-SY5Y human neuroblastoma cells, which express both mu and delta receptors, to examine the effects of halothane on the receptor binding profiles of [3H]diprenorphine (DPN), an opioid receptor antagonist, and [3H] [D-Ala2,MePhe4, Gly(ol)5]enkephalin (DAMGO), a mu receptor selective agonist.
Spec (examine) Regulation (effects) of receptor in SH-SY5Y associated with neuroblastoma, antagonist, agonist, enkephalin, opioid receptor and halothane
10) Confidence 0.01 Published 1995 Journal Br J Anaesth Section Abstract Doc Link 8672325 Disease Relevance 0.17 Pain Relevance 0.64
To elucidate the relationship between mu-opioid receptor (MOR) phosphorylation and the regulation of receptor activity, a series of receptor mutants was constructed in which the 12 Ser/Thr residues of the COOH-terminal portion of the receptor were substituted to Ala, either individually or in combination.
Regulation (regulation) of receptor in terminal portion associated with opioid receptor
11) Confidence 0.00 Published 2001 Journal J. Biol. Chem. Section Abstract Doc Link 11278523 Disease Relevance 0 Pain Relevance 0.27
Furthermore, even though mu-receptors and delta-opioid receptors have the same motif encompassing agonist-induced phosphorylation sites, the different agonist-induced internalization properties controlled by these sites suggest differential cellular regulation of these two receptor subtypes.
Regulation (regulation) of receptor associated with agonist and delta opioid receptors
12) Confidence 0.00 Published 2001 Journal J. Biol. Chem. Section Abstract Doc Link 11278523 Disease Relevance 0 Pain Relevance 0.45
The significance of resensitization of the internalized receptor in affecting receptor desensitization was demonstrated further with human neuroblastoma SHSY5Y cells that expressed a low level of mu-opioid receptor.
Regulation (affecting) of receptor associated with neuroblastoma and opioid receptor
13) Confidence 0.00 Published 2000 Journal Mol. Pharmacol. Section Abstract Doc Link 10908307 Disease Relevance 0.10 Pain Relevance 0.45
In this context, Receptor Ck, a cell-surface receptor specific for the cholesterol moiety in lipoprotein particles [13], may be a good candidate for the regulation of hTERT transcription.
Regulation (regulation) of Receptor
14) Confidence 0.00 Published 2006 Journal BMC Cell Biol Section Body Doc Link PMC1351175 Disease Relevance 0.50 Pain Relevance 0.03
The GABA-a receptor mediates the effect of structurally diverse anaesthetics [1] and is a key target for intravenous hypnotics including etomidate, thiopentone, alphaxalone and propofol [2,3].
Regulation (target) of receptor associated with gaba
15) Confidence 0.00 Published 2010 Journal BMC Anesthesiol Section Body Doc Link PMC2914736 Disease Relevance 0.08 Pain Relevance 0.05
A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietin-induced reduction of the renal cortical blood flow.
Regulation (effect) of receptor in blood associated with antagonist
16) Confidence 0.00 Published 1999 Journal Urol. Res. Section Title Doc Link 10550517 Disease Relevance 0.53 Pain Relevance 0.15
The present study was performed to clarify the effect of a selective ET-A receptor antagonist, S-0139, on EPO-induced RCBF reduction.
Regulation (effect) of receptor associated with antagonist
17) Confidence 0.00 Published 1999 Journal Urol. Res. Section Abstract Doc Link 10550517 Disease Relevance 0.50 Pain Relevance 0.09
These data demonstrate that A-836339 is a useful tool for use of studying CB(2) receptor pharmacology and for investigation of the role of CB(2) receptor modulation for treatment of pain in preclinical animal models.
Regulation (modulation) of receptor associated with pain
18) Confidence 0.00 Published 2009 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 18931146 Disease Relevance 0.70 Pain Relevance 0.93
These results indicate the importance of knowing both receptor expression patterns in normal and diseased tissue as there is the potential to modulate receptor function with splice variant selective drugs.


Regulation (modulate) of receptor
19) Confidence 0.00 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644495 Disease Relevance 0.09 Pain Relevance 0
Our findings point to the need for further studies to define the role of BDNF in the human IVD and to investigate regulatory events, especially those related to mechanoregulation, which regulate the expression of BDNF and its receptor in the human IVD.


Regulation (regulate) of receptor
20) Confidence 0.00 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575628 Disease Relevance 0.17 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox